培美曲塞单药治疗复治晚期肺腺癌45例临床观察  

作　　者：董益忠[1] 张亚平[1] 毕延智[1] 盛桂凤[1] 凌扬[1] 

机构地区：[1]苏州大学附属常州肿瘤医院肿瘤内科,213001

出　　处：《当代医学》2012年第31期39-41,共3页Contemporary Medicine

摘　　要：目的探讨培美曲塞单药治疗晚期肺腺癌的疗效及不良反应。方法选取经病理学或细胞学确诊的复治晚期肺腺癌45例作为研究对象。采用培美曲塞500mg/m2,第1d静脉滴注,每3周重复。评价疗效及不良反应。结果 45例中无完全缓解病例,部分缓解12例,稳定18例,进展15例,疾病控制率为66.7%(30/45),中位无疾病进展时间为(PFS)3.1个月,中位生存期(OS)为6.6个月,1年生存率为24.5%。主要不良反应为粒细胞下降、贫血和胃肠道反应。结论培美曲塞单药治疗复治晚期肺腺癌疗效确切,不良反应发生率低,耐受性较好。Objective This study was to evaluate the efficacy and side effects of pemetrexed alone in the treatment of PulmonaryAdenocarcinoma.Methods Patients with advanced NSCLC who had failed to previous chemotherapy were enrolled in this study and all of these patients had been confirmed with pathology or cytology.Single agent regimen：patients received pemetrexed 500 mg/m2 on day 1,by intravenous infusion,with every 21 days.All patients who received 2 or more cycles could be evaluated.Results There was no case with complete response.12 cases had partial response,18 had stable disease and 15 cases had progressive disease.The disease control rate was 66.7%（30/45）.The median progress-free survival was 3.1 months,The median overall survival（OS）was 6.6 months,and 1-year survival rate 24.5%.The common adverse effects were leucopenia,anemia and gastrointestinal response.Conclusion Pemetrexed is effective and feasible for advanced recurrent pulmonary adenocarcinoma.

关 键 词：培美曲塞 复发 肺腺癌 

分 类 号：R734.2[医药卫生—肿瘤]